Traditional drug development is notoriously inefficient, characterized by high costs, low ROI, and significant attrition rates. To combat these challenges, the pharmaceutical industry is increasingly adopting "digital twins," which are computational in silico simulations used to test feasibility before physical realization.
These twins can simulate systems or processes, and now there are digital twin solutions on the market capable of simulating individual patients at a molecular level, to predict drug performance and allow a patient to serve as their own control in "n of 1" studies.
While these advancements promise faster, lower-cost trials, they face a significant hurdle: the “black box” problem of artificial intelligence (AI).
Transparent box
Historically, predictive models relied on statistical machine learning that identified patterns across vast datasets, such as electronic health records or molecular profiles. While effective at finding associations, these models often lack scientific interpretability. For clinicians and regulators, an algorithm that predicts toxicity or efficacy without explaining the underlying biological mechanism is difficult to trust in high-stakes decision-making.
To bridge this trust gap, the field has embraced mechanistic and Bayesian modeling. Unlike purely statistical AI, mechanistic architectures encode known physiological and pharmacological processes. By applying Bayesian inference, developers can utilize structured assumptions from existing scientific knowledge or multi-omics datasets, otherwise known as biological “priors,” to navigate incomplete or fragmented clinical data.
Crucially, these frameworks provide traceable, reasoned probabilities and quantified confidence intervals. Instead of an opaque binary prediction, they offer principled uncertainty estimates, allowing trial designers to understand the “why” behind a forecasted outcome.
Regulatory catalyst
The regulatory apparatus is moving decisively to match this scientific evolution. The enactment of the FDA Modernization Act 2.0 in 2022 removed historical statutory language that explicitly required pre-clinical animal testing, authorizing sponsors to utilize human-relevant “non-clinical tests,” also known as New Approach Methodologies (NAMs). While NAMs (e.g., organ-on-a-chip platforms and cell-based assays) offer direct human relevance, they still fragment human biology into isolated components. Digital twins, however, promise to integrate these fragmented biological layers alongside vast genomic, transcriptomic, and proteomic datasets to generate comprehensive, systems-level predictions of therapeutic efficacy.
In January 2026, the FDA issued a landmark draft guidance titled, “Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products.” This document outlines how Bayesian calculations can govern interim analyses, dose selection, and primary inference for drug effectiveness. A similar approach was announced by the EMA earlier this year. This shift is transformative for rare disease research, where recruiting sufficient patient populations for traditional randomized trials is often impossible; Bayesian methods allow developers to leverage historical data and pre-clinical evidence to infer outcomes in data-limited cohorts.
Future of clinical evidence
The regulators’ endorsement represents a fundamental change in evaluation: regulators are moving away from validating the final output of a “black box” and toward evaluating the transparency and scientific validity of the underlying biological assumptions. This aligns with “plausible mechanism” pathways, which require AI predictions to align coherently with established biological knowledge.
As the industry moves away from inefficient trial designs, the integration of advanced computational simulations has become an immediate regulatory priority and was discussed at length at last week’s RAPS conference in Lisbon. By embracing models that deliver traceable, biologically plausible insights, the biotechnology sector is finally equipped to unlock the full potential of in silico trials, accelerating the delivery of safe, life-saving therapeutics.
